Latest Breaking News On - Ivan davis - Page 1 : comparemela.com
Ebola, especially when bureaucratic red tape is holding up companies from developing vaccines for just these kind of outbreaks . With more on this, david dod, chairman of the board of directors at geovax. Dr. Kevin campbell, assistant professor of medicine at university of the North Carolina. Welcome to you both. David, i want to start with you because youre the perfect guest for this segment because your company, geovakx is in process developing a vaccine for ebola. What are the hurdles putting together a drug that could combat this deadly disease . Yes, thank you. First of all, thank you for allowing me to come on today to talk about this very important development. Were developing two vaccines for ebola. One will address the current strain for epidemics such as were currently experiencing. And the other one will address all three strains that are lethal to humans. The challenge in developing of course is always is funding. But more important to demonstrate three important elements,
New-yorkUnited-statesCanadaTampaFloridaNorth-carolinaBrooklynMissouriTexasAlaskaPhiladelphiaPennsylvania